Treace Medical Concepts, Inc. - Common Stock (TMCI)
4.4650
-1.7650 (-28.33%)
NASDAQ · Last Trade: Nov 7th, 10:14 PM EST
Detailed Quote
Previous Close
6.230
Open
3.900
Bid
4.400
Ask
4.530
Day's Range
3.401 - 4.501
52 Week Range
3.401 - 10.79
Volume
6,682,555
Market Cap
273.84M
PE Ratio (TTM)
-5.581
EPS (TTM)
-0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
521,535
Chart
About Treace Medical Concepts, Inc. - Common Stock (TMCI)
Treace Medical Concepts Inc is a medical technology company focused on developing and commercializing innovative solutions for foot and ankle surgery. The company specializes in advanced surgical techniques and devices aimed at improving patient outcomes, particularly in conditions such as bunions and other foot deformities. Treace Medical provides surgeons with minimally invasive products that enhance the precision and efficiency of surgical procedures, ultimately helping patients achieve quicker recovery times and improved mobility. Through ongoing research and development, Treace Medical strives to remain at the forefront of the orthopedic medical device industry. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences.
PONTE VEDRA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the third quarter ended September 30, 2025.
PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and MTA3D™ clinical studies at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2025 in Savannah, Georgia from September 10-13, 2025.
